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ABSTRACT  
Uncovering the molecular mechanisms of Mesial temporal lobe epilepsy (MTLE) is 
critical to identify therapeutic targets. In this study, we performed global protein 
expression analysis of a kainic acid (KA) MTLE mouse model at various time-points 
(1d, 3d, 30d post KA injection -dpi), representing specific stages of the syndrome. 
High resolution liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS), in combination to label-free protein quantification, using three processing 
approaches for quantification, was applied. Following comparison of KA versus 
NaCl-injected mice, 22, 53 and 175 proteins were differentially (statistically 
significant) expressed at 1, 3 and 30dpi respectively, according to all 3 quantification 
approaches. Selected findings were confirmed by multiple reaction monitoring LC-
MS/MS. As a positive control, the astrocyte marker GFAP was found to be 
upregulated (3dpi:1.9 fold; 30dpi:12.5 fold), also verified by IHC. The results 
collectively suggest that impairment in synaptic transmission occurs even right after 
initial status epilepticus (1dpi), with neurodegeneration becoming more extensive 
during epileptogenesis (3dpi) and sustained at the chronic phase (30dpi), where also 
extensive glial and astrocyte–mediated inflammation is evident. This molecular 
profile is in line with observed phenotypic changes in human MTLE, providing the 
basis for future studies on new molecular targets for the disease.  
KEYWORDS 
Epilepsy, MTLE, Kainic acid, LC-MS/MS, proteomics 
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INTRODUCTION 
The Mesio-Temporal Lobe Epilepsy (MTLE) syndrome is the most common form of 
intractable focal epilepsies. It is well accepted that most MTLE patients have 
experienced during early childhood an insult such as complex febrile seizures, head 
trauma, intracerebral infections or ischemia episodes1, 2. This initiating insult triggers 
cascades of molecular mechanisms over a period of several years during which no 
clinical symptoms are observed. This so-called “silent period” corresponds to the 
progressive development of epilepsy (i.e. epileptogenesis) ultimately leading to 
recurrent focal seizures generated in the mesio-temporal limbic structures3, 4. This 
period appears as a time of intense functional and morphological reorganization 
including neurodegeneration, gliosis, axonal damage or sprouting, dendritic plasticity, 
blood–brain barrier damage, recruitment of inflammatory cells into the brain tissue, 
reorganisation of the extracellular matrix and of the molecular architecture of 
individual neuronal cells5. To better understand the molecular mechanisms underlying 
epileptogenesis, microarrays have been used in animal models6-11 and human 
samples12. Yet, no comprehensive studies at the proteomic level have been performed. 
Here, we used a mouse model of MTLE induced by intra-hippocampal injection of 
kainate (KA) which reproduces most of the histopathological and electrophysiological 
features of human MTLE13-16. Indeed, in this model, spontaneous focal epileptic 
seizures associated with mild behavioral expression develop progressively in the 
hippocampus, leading to a stereotyped pattern at 16-18 days following KA injection, 
which remains stable for several months, with only occasional propagation to the 
cortex, as in MTLE patients16, 17. In addition, cell loss in CA1, CA3 and hilus areas, as 
well as astrocyte proliferation and granule cell dispersion are observed in the kainate-
injected hippocampus, that are highly reminiscent of the hippocampal sclerosis 
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observed in most MTLE patients13, 14, 18. In this study animals were sacrificed at 
specific time-points post KA injection: 1 day post injection (dpi), during the silent 
period after the completion of the focal status epilepticus (SE) when no discharges are 
observed; 3dpi, during epileptogenesis, when spontaneous seizures start to occur in 
the hippocampus region, and 30dpi, which corresponds to the chronic phase with 
recurrent focal discharges.  
The employment of label-free strategies for relative protein quantification has gained 
prominence in the last years due to their ease of use, since no additional sample 
preparation or chemical modification steps are required19. When compared to stable 
isotope labeling approaches, they provide a simpler method, while also exhibiting a 
larger dynamic range for estimating relative protein abundance20.  
The most commonly used label-free quantification approach is spectral counting (SC), 
where relative protein abundance is measured by the number of MS/MS spectra 
corresponding to all peptides assigned to a protein. Another strategy is based on the 
sum of the Total Ion Current (TIC) of the MS/MS spectra assigned to the peptides for 
a given protein21. In more recent studies, the intensity of the precursor ion (MS1) is 
also used as a quantitative measure22. SC is easy to use, reproducible and highly 
sensitive for subtle changes in protein abundance. However, it is considered 
inaccurate for the calculation of fold change of low abundance proteins, as it is 
influenced by the protein size21. TIC, which is based on the MS/MS spectrum 
intensity, shows larger dynamic range than SC, improved sensitivity for low 
abundance changes, but suffers from irreproducibility and signal saturation in highly 
abundant proteins19. Quantification based on precursor ion intensity is considered 
highly accurate but requires high resolution precursor ion measurements to ensure 
neighboring peaks are distinguished23. 
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Here we employed the combination of all three approaches, in particular (i) SC, (ii) 
sum of top three TIC values of the peptides of a given protein (top3TIC), and (iii) sum 
of top three intensities from three precursor ions of a protein (top3 precursor intensity, 
PI). It has been suggested that top three approaches based on MS1 peak intensity are 
directly proportional to protein abundance and are associated with fewer errors than 
SC24. Since apparently each of these quantification approaches, which rely on 
different characteristics of the mass spectra to estimate peptide amounts, has certain 
advantages and limitations, their combined use should increase the reliability of 
identified protein changes21, 23. 
The aim of this study was to characterize in detail the temporal protein changes 
associated with KA-induced MTLE in a mouse model, in order to characterize the 
disease development at the proteomic level, currently missing in the field, and in 
parallel provide further experimental evidence for the molecular relevance of this 
model to human epilepsy. Taken together our results indicate that during 
epileptogenesis (3dpi) and more importantly during the chronic phase of the 
syndrome (30dpi), signs of neurodegeneration as well as changes in inflammatory 
response are observed, possibly through the activation of glial cells and astrocytes.  
EXPERIMENTAL PROCEDURES 
Animals  
Experiments were conducted on adult C57Bl/6j male mice (Janvier, Le-Genest-St-
Isle, France; 8-10 weeks of age; 20-25g). After surgery, they were housed in 
individual cages with food and water ad libitum and kept in a 12h light-dark cycle at 
room temperature (RT). All animal procedures were carried out at the high 
technology animal platform, Institute Jean Roget (University Grenoble Alpes) and at 
the Grenoble-Institute for Neuroscience, in accordance with the guidelines of the 
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European Committee Council Directive 2010/63/EU. All efforts were made to 
minimize animal suffering and to reduce the number of animals used. The following 
procedures were approved by the local ethical committee of the University Grenoble 
Alpes and the Grenoble-Institute for Neuroscience (Protocols #P49, #274).  
Intrahippocampal injection  
Mice were anesthetized using a mixture of xylazine (4mg/kg, i.p.) and chloral hydrate 
(400mg/kg, i.p.) and placed in a stereotactic frame in a flat skull position. They were 
injected with either KA or NaCl (0.9%) as previously described14-16, 25. Briefly, a 
stainless steel cannula (outer diameter, 0.28mm) connected to a 0.5µL micro-syringe 
(Hamilton, Bonaduz, Switzerland) via PE20 tubing containing distilled water, was 
filled with a 20mM KA solution (Sigma, Lyon, France) in 0.9% sterile NaCl and 
positioned in the right dorsal hippocampus (AP = -2, ML = -1.5, DV = -2mm from 
bregma). Mice received 50nL of the KA solution (1nmol) using a micro-pump 
(CMA/100, Carnegie Medicin, Stockholm, Sweden). After injection, the cannula was 
left in place for an additional 1 min to avoid reflux along the cannula track. 
After recovery from anesthesia (i.e, about 2h) the animals were observed to visually 
determine their behavior during the KA-induced SE and confirm impact of the 
injection. It should be noted that mice were not implanted with electrodes in these 
experiments to avoid any possible interference on biochemical parameters. However, 
as published previously14-16, 25, observations in mice of rotations, postural asymmetry, 
forelimb clonies and lack of nest building when soft material is provided, during the 
24h that follow KA injection, are very robust indicators of the focal status in this 
model. Based on this phenotypic characterization, no differences in the severity of the 
phenotype could be observed among the animals. Moreover, KA-injected mice 
exhibiting recurrent hippocampal paroxysmal discharges, always show astrocytic 
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proliferation and increased GFAP expression15, 26. As described in the results section, 
for each sample included in the analysis, the overexpression of GFAP was verified by 
the proteomic analysis, as an "internal" positive control. 
Hippocampal dissection  
One, three or 30 days after intrahippocampal injection of either KA or NaCl (n=5 
mice/group), mice were decapitated. Their brain was rapidly removed from the skull 
at 4°C. Both the injected and non-injected hippocampi were dissected and the anterior 
part was snap frozen in liquid nitrogen. The entire procedure never exceeded 2 min. 
All tissue samples were kept at -80°C until further processed for proteomic analysis. 
Proteomic sample preparation  
The injected dorsal hippocampi were processed with the filter-aided sample 
preparation protocol (FASP) (n=5 mice/group)27. In more detail, the tissue samples 
were homogenized in a 0.1M Tris-HCl pH 7 lysis buffer, supplemented with 4% SDS 
and 0.1M DTT. Following that, protein concentration of the supernatant was 
determined by Bradford assay and 200µg of protein per sample was mixed with 0.2 
mL of 8M urea in 0.1M Tris/HCl, pH 8.5 (urea solution), loaded into 30kDa Amicon 
Ultra Centrifugal Filters, Ultracel (Merck Millipore) and centrifuged at 14000g for 15 
min. The concentrates were diluted in the devices with 0.2mL of urea solution and 
centrifuged again. After centrifugation, the concentrates were mixed with 0.1mL of 
50mM iodoacetamide in urea solution and incubated in the dark, at RT for 20 min 
(alkylation), followed by centrifugation for 10 min. Then, the concentrate was diluted 
with 0.1mL of urea solution and concentrated again by centrifugation. The resulting 
concentrate was diluted with 0.1mL of 50mM NH4HCO3, pH 8 and concentrated 
again by centrifugation. This step was repeated once. Finally, samples were diluted 
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with 40µL of 25mM NH4HCO3 containing 2µg of trypsin. After overnight digestion at 
RT, peptides were collected by centrifugation of the filter units for 10 min in new 
tubes. The filter units were washed with another 40µL of 50mM NH4HCO3 and 
remaining peptides were collected in the same tube. The eluates were lyophilized and 
stored at RT.  
LC–MS/MS analysis 
The peptide mixtures after lyophilization were resuspended in water (100µl) and were 
analysed on a Dionex Ultimate 3000 RSLS nano-flow system (Dionex, Camberly 
UK). 5µl of each sample were loaded onto a Dionex 0.1×20mm 5µm C18 nano trap 
column at a flowrate of 5µl/min. The loading solution consisted of 98% 0.1% formic 
acid and 2% acetonitrile. Once loaded onto the trap column the sample was then 
eluted onto an Acclaim PepMap C18 nano-column 75µm × 50cm, 2µm 100Å at a 
flowrate of 0.3µl/min. The trap and nano-flow column were maintained at 35°C. The 
samples were eluted with a gradient of solvent A: 0.1% formic acid verses solvent B: 
80% acetonitrile starting at 1% B for 5 min rising to 5% B at 10 min then to 25% B at 
360 min then 65% B at 480 min. The column was then washed and re-equilibrated 
prior to injection of the next sample. 
The eluate from the column was applied to a Proxeon nano-spray ESI source (Thermo 
Fisher Hemel UK) operating in positive ion mode into an Orbitrap Velos FTMS 
(Thermo Finnigan, Bremen, Germany). Ionization voltage was 2.6kV and the 
capillary temperature was 200°C. The mass spectrometer was operated in MS/MS 
mode scanning from 380 to 2000amu. The top 20 multiply charged ions were selected 
from each scan for MS/MS analysis and the fragmentation method was CID at 35% 
collision energy. The resolution of ions in MS1 was 60,000 and 7,500 for CID MS2 
which was performed in the Orbitrap. The data was acquired using data dependent 
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settings with dynamic exclusion enabled, a repeat count of 1 with exclusion duration 
of 15 seconds. The threshold for triggering a MS/MS event was set at 10,000 counts 
and the isolation width of precursor ion was 2, charge state screening was enabled and 
unassigned charge states and a charge state of 1 were rejected. 
LC–MS/MS -data processing 
Tandem mass spectra from LC–MS/MS analysis of the samples were uploaded to 
Thermo Proteome Discoverer 1.4 software (Thermo Scientific, Hemel Hempstead, 
UK). Precursor peptide mass tolerance was set at 10ppm and 0.4Da for MS/MS 
fragment ions. Peptide and protein identification was performed with the SEQUEST 
search engine. For peptide identification the latest version of the UniProt SwissProt 
database of Mus musculus proteome containing only reviewed canonical sequences 
(17046 entries, 29/10/2014) was used, considering trypsin enzyme digestion and 
allowing for a maximum of one missed cleavage. Carbamidomethylation of cysteine 
was specified as a fixed modification and deamidation of asparagine and glutamine 
and oxidation of methionine were specified as variable modifications in SEQUEST. 
All acquired information regarding the identified proteins, including score, sequence 
coverage, number of assigned peptides, protein area, as well as peptide sequences and 
areas, are provided in Supplementary Table 1.  
Scaffold (version Scaffold_3.6.3, Proteome Software Inc., Portland, OR) software 
was used to validate MS/MS based peptide and protein identifications at each time-
point. Peptide and protein identifications were accepted if they could be established at 
greater than 90.0% and 99.0% probability, respectively, by the Peptide Prophet and 
Protein Prophet algorithm28, 29. Proteins that contained similar peptides and could not 
be differentiated solely based on MS/MS analysis were grouped to satisfy the 
principles of parsimony. Using a target decoy database, a peptide false discovery rate 
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lower than 0.05% was determined. Protein identifications were accepted if they 
included at least 2 identified peptides in at least one biological sample.  
Label-free quantification of protein expression levels in the resulting hits was 
performed in Scaffold, using 3 different quantification approaches: Spectral counting 
(SC), the sum of the top three TIC values of the peptides of a given protein, and the 
sum of the top three intensities from three unique peptides (MS1 intensity) of a 
protein (Precursor intensity, PI). SC corresponds to the “sum of all unweighted 
spectrum counts of each MS samples”. TIC is the “sum of the areas under all the 
peaks contained in a MS/MS spectrum. Scaffold assumes that the area under a peak is 
proportional to the height of the peak and approximates the TIC value by summing 
the intensity of the peaks contained in the peak list associated to a MS/MS sample”. 
Data were normalized by Scaffold. Following that, fold expression difference was 
calculated in KA-injected mice versus NaCl-injected mice at each time-point and 
statistical analysis was performed with the Student's t-test (Supplementary Table 1).  
Immunohistochemistry 
All animals were perfused transcardially with 4% paraformaldehyde in phosphate 
buffer saline (PBS) (n=4 mice/group). Brains were cryoprotected in 20% sucrose in 
PBS, embedded in cryomedia (OCT), sectioned (40µm) with a cryostat in coronal 
orientation and were further processed for immunohistochemistry assays. Free-
floating sections were pre-incubated in 0.25% Triton X-100 in PBS for 30 minutes at 
RT and then in PBS containing 2% bovine serum albumin (BSA, blocking solution) 
as a blocking agent for 30 minutes at RT. Next, sections were incubated overnight in 
BSA containing 0.1% Triton X-100 and the primary antibody at 4˚C. After rinsing 
four times with PBS, sections were incubated for 2h at RT with fluorescence-
conjugated secondary antibody diluted in PBS. Following that, nuclei were stained 
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with Hoechst dye, diluted 1:1000 in PBS. Finally, sections were rinsed 4 times in PBS 
and mounted on slides. Microscopic images were obtained using a Zeiss confocal 
microscope. 
Multiple reaction monitoring LC-MS/MS - Sample Preparation 
Peptides corresponding to 100µg total protein tissue extract from the FASP 
preparation were used for Multiple reaction monitoring (MRM) LC-MS/MS analysis 
(30dpi; n=5/group). The peptide mix was desalted with Zip-tips (Thermo Scientific), 
dried using a vacuum centrifuge and pellets were solubilized in appropriate volume of 
0.1% formic acid (FA) to 1µg/µL final concentration. 
MRM LC-MS/MS assay design and method development 
Liquid chromatography was performed using an Agilent 1200 series nano-pump 
system (Agilent Technologies, Inc., Palo Alto, CA), coupled with a C18 nano-column 
(150mm × 75µm, particle size 3.5µm) from Agilent. Peptide separation and elution 
was achieved with a 40 min 5-35% ACN/water 0.1% FA gradient at a flow rate of 
300nl/min. Four microliters of each sample were injected.  
Tryptic peptides were analyzed on an AB/MDS Sciex 4000 QTRAP with a nano-
electrospray ionization source controlled by Analyst 1.5 software (Sciex). The mass 
spectrometer was operated in MRM mode, with the first (Q1) and third quadrupole 
(Q3) at 0.7 unit mass resolution. At least three transitions were recorded for each 
peptide. Optimum collision energies for each transition were automatically calculated 
by the Skyline software. Detailed information about the acquisition method and the 
used parameters are provided in Supplementary Table 2 (supporting information 
document).  
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Proteotypic peptide selection for MRM LC-MS/MS 
Proteotypic peptides for GFAP, Apolipoprotein-E, Clusterin, Vimentin, Cystatin-C, 
Galectin-1, Gelsolin, and Homer 1 were selected from the list of proteotypic peptides 
provided by Skyline30. The final selection was based on the quality of the MS/MS 
spectrum of each peptide in the mouse spectral library (NIST_mouse_IT_2012-04-
21_7AA.splib), downloaded from NIST (National Institute of Standards and 
Technology, http://www.nist.gov/), and on the score and number of observations in 
MS-based proteomics experiments as provided from PeptideAtlas 
(www.peptideatlas.com)31. One up to three proteotypic peptides with at least 3 
transitions each, were finally selected to be tested. 
RESULTS 
Intrahippocampal kainate injection induces initial status epilepticus and GFAP 
upregulation 
As extensively described in previous studies, a single dose of KA (1nmol in 50nl) 
induced an initially focal status epilepticus lasting up to 15-20h, during which animals 
showed mild asymmetric clonic movements of the forelimbs, rotations, and/or 
behavioral arrests13-18. Following KA administration, all mice evaluated in this study 
had behavioral signs of SE on day 0. Then, they progressively displayed 15-20 sec 
duration focal seizures associated with behavioral arrest, chewing and head nodding 
during the first 2-3 weeks14, 16. As described earlier (methods), mice were not 
implanted with electrodes in these experiments. Efficiency of injection was instead 
monitored by observing specific phenotypic and behavioral characteristics during the 
24h that follow KA injection (rotations, postural asymmetry, forelimb clonies and 
lack of nest building when soft material is provided). Based on these characteristics, 
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no differences in the severity of the phenotype could be observed among the animals. 
In addition, activation of astrocytes and reactive astrogliosis has been reported as a 
hallmark of neuronal loss in neurodegenerative disorders and epilepsy32-34. Previous 
studies have established that KA-injected mice exhibiting recurrent hippocampal 
paroxysmal discharges always show astrocytic proliferation and increased GFAP 
expression15, 25. GFAP is therefore considered as a positive control, reflecting the 
efficiency of the KA injection and focal status25, 35. As shown in Figure 1A, all mice 
included in the study exhibited an increase of GFAP expression after KA injection in 
comparison to NaCl treated mice according to the proteomics analysis (at 3dpi ≥1.5 
fold and at 30dpi ≥9 fold, p<0.05, Student’s t-test). GFAP upregulation was further 
confirmed by immunohistochemistry, showing a gradual increase of 1.6, 2 and 3.9 
fold at 1dpi, 3dpi and 30dpi respectively, in comparison to NaCl treated mice (Figure 
1 B, C, n=4/group). 
Label-free quantitative proteomic analysis  
Global protein analysis of KA and NaCl-injected hippocampi of three distinct time-
points by LC-MS/MS resulted in the detection of a total of 1309 proteins at 1dpi, 
1481 at 3dpi and 1280 at 30dpi, respectively (Figure 2, Supplementary Table 1). Low 
percentage of variance (Coefficient of variance of less than 21%) in number of 
identified proteins was detected among the different biological replicates per time-
point (Supplementary Figure 1). Good reproducibility rates were observed in all cases 
with 83.5% and 90.5% of proteins identified in at least 3 out of 5 replicates in KA and 
NaCl treated mice at 1dpi, respectively. The respective rates for 3 and 30dpi were 
85.2% (KA) and 87.8% (NaCl) at 3dpi, and 90% (KA) and 83.5% (NaCl) at 30dpi 
(Supplementary Figure 2). To increase reliability of findings a frequency threshold 
was applied and only proteins present in at least 3 out of 5 samples in both groups 
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(KA and NaCl) or uniquely expressed in at least 3 out of 5 KA or NaCl treated mice, 
were considered for further differential expression analysis (Figure 2). 
For the label-free quantification of protein expression changes, three quantification 
approaches were applied in Scaffold software: SC, top three TIC and top three PI. 
Following comparison of KA vs NaCl-injected mice at each time-point and statistical 
analysis, proteins that were differentially expressed (fold change≥1.5 or fold≤0.5) and 
statistically significant (p≤0.05, Student's t-test), in at least one quantification 
approach, were in total 183 (1dpi), 187 (3dpi) and 363 (30dpi) (Supplementary Figure 
3). However, at 1dpi, only 9 proteins were overlapping among the three approaches, 
which corresponds to a range of 8-16% overlap, depending on the performed 
comparison [Supplementary figure 3, A(i)]. Higher overlap was observed at 3 and 
30dpi, with 20-27% and 36-40% overlap among the three quantification approaches, 
respectively [Supplementary figure 3, B(i), C(i)]. Of note, the overlapping proteins of 
all three approaches are not always the ones with the lowest p values. In particular, 
among the top 20 or top 50 of the proteins with the lowest p values per quantification 
approach, only 15-26% proteins were overlapping among all 3 approaches, at each 
time-point (data not shown). 
Overlap was also investigated considering one of the two criteria being fulfilled (e.g. 
either p≤0.05 or fold change≥1.5/fold ≤0.5 but with agreement in expression trends). 
Data show similar overlap when all proteins with p≤0.05 are taken into account [1dpi 
(7.5-14.3%), 3dpi (22.5-29%), 30dpi (38.5-42.5%), Supplementary figure 3 A(ii), 
B(ii), C(ii)], while overlap increases to 40-50% when only the fold change threshold 
is used [1dpi (39.6-56.9%), 3dpi (43.6-48.4%), 30dpi (41-56.7%), Supplementary 
Figure 3 A(iii), B(iii), C(iii)]. Taken together, these data indicate a low number of 
overlapping proteins when the statistical significance in taken into account. We 
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nevertheless decided to consider for further analysis differentially expressed proteins 
as defined by fold change (fold≥1.5 or fold ≤0.5) and statistical significance (p≤0.05, 
Student's t-test), as well as proteins uniquely expressed in at least 3 out of 5 KA or 
NaCl treated mice, according to all 3 quantification approaches. Even though this 
approach apparently decreases the number of shortlisted proteins for further 
investigation, it increases confidence and reliability of highlighted findings, which is 
important considering the relatively small sample size (n=5/group) and general trend 
of such multi-parametric omics analyses towards providing false associations. 
According to these criteria, the highest number of differentially expressed proteins 
was observed at 30dpi (175 proteins), whereas 22 proteins were differentially 
expressed at 1dpi and 53 proteins at 3dpi (Figure 2, Supplementary Table 1).  
Immediate protein expression response after SE (1dpi) 
Proteomic analysis revealed that, following KA administration, mice that had 
developed SE showed a small number of proteins being regulated, 1 day post KA 
injection. In particular, twenty-two proteins were found to be differentially expressed 
(Table 1). Interestingly, most of the differentially expressed proteins at 1dpi were 
downregulated in KA-injected mice or expressed only in control animals (NaCl-
injected mice). Well-known proteins involved in synaptic plasticity, such as 
Neurabin-2 and Neurochondrin, or involved in neurodegeneration such as Homer1 
were downregulated by 0.66, 0.33 and 0.53 fold, respectively36-38. Additionally, other 
proteins expressed in neuronal cells were detected only in NaCl-injected animals, 
such as Ataxin-10, Shank3 and WD repeat-containing protein 4739-41. On the other 
hand, some proteins that have also been shown to be expressed by neural cells were 
upregulated, such as nucleophosmin (2 fold), or detected only in KA-injected animals 
such as SPARC-like protein 1 and Hemopexin42-44.  
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Early protein expression response during epileptogenesis (3dpi) 
The proteomic data at 3dpi depicted 53 proteins which were significantly changed 
following KA administration, and in particular 21 proteins were upregulated or 
detected only in KA-injected mice, whereas 32 proteins were downregulated or 
detected only in control (NaCl-injected) animals (Supplementary Table 1). As shown 
in Figure 3A, and following grouping based on gene ontology (using Panther45), at 
3dpi several differentially expressed proteins following KA injection were associated 
to neuron projection development and regulation of synaptic plasticity, as well as 
microglial cell and astrocyte activation (Table 2). In brief, most of these proteins, such 
as Neurabin-2, Brain-specific angiogenesis inhibitor 1-associated protein 2, Src 
substrate cortactin, Sodium- and chloride-dependent GABA transporter 1 were 
downregulated 0.3, 0.36, 0.47 and 0.53 fold, respectively. Similarly, other molecules 
involved in neuronal synaptic processes, such Brain-specific serine/threonine-protein 
kinase 1, A-kinase anchor protein 5 and Shank3 (SH3 and multiple ankyrin repeat 
domains protein 3) were detected only in NaCl-injected mice. By contrast, proteins 
found to be significantly upregulated at 3dpi, were indicative of glial and astrocyte 
cell differentiation as well as lymhpocyte migration. These include Moesin (8.3 fold), 
Clusterin (2.73 fold), GFAP (1.9 fold) and Vimentin (2 fold) (Table 2). 
Protein expression response during chronic phase of epilepsy (30dpi) 
In the hippocampi collected at 30dpi, i.e., during the chronic phase of epilepsy, 175 
proteins were found to be differentially expressed, in comparison to NaCl-injected 
animals. In particular, 97 proteins were found to be upregulated or detected only in 
KA-injected mice, whereas, 78 proteins were detected as downregulated in KA-
injected mice or detected only in control animals (Supplementary Table 1). A 
significant number of the dysregulated proteins were related to neuron and axon 
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regeneration, regulation of synaptic plasticity, inflammatory response, microglial cell 
activation, using grouping based on gene ontology (Panther45), ( Figure 3 B, C). All 
proteins related to these categories are listed in Table 3. Similar results regarding the 
GO terms enriched in the differentially expressed proteins were also obtained 
following data analysis using Cytoscape software46 (data not shown). In addition and 
in support of the specificity of this finding, when Panther analysis was performed 
using 3 randomly picked similar sized protein datasets or the whole dataset of non-
differentially expressed proteins, in general a lower enrichment of GO terms related to 
neuronal processes or immune response was obtained in comparison to the respective 
analysis of differentially expressed proteins (e.g. at 30dpi terms related to neuronal 
processes showed an enrichment of 2.29-10.86% in the differentially expressed 
proteins in comparison to 1.1-4.1% and 2-5.58% enrichment in randomly picked 
similar sized protein dataset or in the whole dataset of non- differentially expressed 
proteins, respectively). 
The vast majority of proteins related to neuronal responses were downregulated or 
detected only in NaCl-injected animals, which could be an indication of 
neurodegeneration induced in the KA-injected animals. These included Src substrate 
cortactin (0.13 fold), Drebrin-like protein (0.2 fold), Paralemmin-1 (0.2 fold), Band 
4.1-like protein 3 (0.26 fold), Disks large homolog 2 (Dlg2) (0.23 fold), Disks large 
homolog 4 (Dlg4) (0.3 fold) and Map1b (0.43 fold), all significantly down-regulated. 
In addition, some proteins found to be down-regulated at 3dpi appeared consistently 
also down-regulated at 30 days post KA injection, as shown in Table 4. These 
included: Brain-specific angiogenesis inhibitor 1-associated protein 2 (3dpi: 0.37 fold, 
30dpi: 0.16 fold), Neurabin-2 (3dpi: 0.3 fold, 30dpi: 0.4 fold), Map1a (3dpi: 0.6 fold, 
30dpi: 0.43 fold), Map2 (1dpi: 0.53 fold, 3dpi: 0.53 fold, 30dpi: 0.43 fold) and 
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Sodium- and chloride-dependent GABA transporter 1 (3dpi: 0.53 fold, 30dpi: 0.37 
fold). Table 4 highlights all proteins which are differentially expressed in more than 
one time-point. Interestingly, these markers show consistent upregulation or 
downregulation during the progression of the epileptic syndrome.  
Moreover, several 14-3-3 proteins commonly expressed in the brain were 
downregulated, including beta/alpha (0.59 fold), gamma (0.63 fold), epsilon (0.66 
fold), eta (0.59 fold), theta (0.59 fold). 
 At the same time-point, consistent upregulation of proteins related to inflammation 
and immune response as well as astrocyte and glial cell activation was observed 
following KA injection, in comparison to controls (Figure 3C, Table 3, Table 4). In 
particular, several proteins mainly expressed by activated glial cells and astrocytes 
were upregulated, such as Clusterin (37.5 fold), GFAP (12.5 fold), Vimentin (8 fold), 
Gelsolin (6.4 fold), Apolipoprotein E (5.2 fold) and Allograft inflammatory factor 1 
(Iba-1) (detected only in KA-injected mice). Additionally, proteins indicative of 
inflammation and immune response were also found to be mostly upregulated or 
detected only in KA-injected animals, including Cystatin-C (4.1 fold), Alpha-2-
macroglobulin, Complement C4-B, Galectin-1, CD44 antigen and Platelet-activating 
factor acetyl hydrolase, all detected only in KA mice.  
Targeted proteomic MRM LC-MS/MS  
From the differentially expressed proteins at 30dpi, several molecules which are 
predominantly expressed by astrocytes and microglia such as GFAP, Vimentin, 
Clusterin, Apolipoprotein E and Gelsolin, as well as molecules that are abundantly 
present in inflammation sites such as Cystatin-C and Galectin-1, were selected for 
validation with an MRM targeted proteomic approach. Selection of these proteins for 
further validation was based on biological relevance (e.g. involvement in activation of 
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microglia and inflammation), as well as ability to develop MRM assays for their 
measurement (availability of proteotypic peptides of good chromatographic and mass 
spectrometric properties). MRM LC-MS/MS analysis confirmed the upregulation of 
all these molecules upon KA injection (Figure 4, Table 5, Supporting information-
Table 3). As shown, GFAP and Apolipoprotein E were detected with three and two 
peptides, respectively, all following the same trend of expression. In these 
experiments, Homer 1, which was detected by LC-MS/MS in both KA and NaCl-
injected animals at equal levels at 30dpi, was used as a control. Indeed, Homer 1 was 
also found to be equally expressed in KA and NaCl-injected hippocampi by MRM 
LC-MS/MS.  
DISCUSSION 
In the present study, we provide an overview of the temporal proteomic regulation 
that takes place during development of epilepsy, in a well-defined model of MTLE16, 
25. For this reason, distinct time-points after KA injection were selected for further 
analysis. The first time-point, 1 day post injection, is during the silent period, right 
after the initial seizure, when no discharges are observed upon completion of the focal 
status epilepticus. The second time-point, 3 days post injection, is when epilepsy 
develops (epileptogenesis), and spontaneous seizures start to occur in the 
hippocampus region; whereas the 30dpi time-point, corresponds to the chronic phase 
of epilepsy with recurrent stereotyped focal discharges47. This model of intra-
hippocampal KA injection has been well characterized in many studies as 
successfully reproducing most of histopathological and electrophysiological features 
of human MTLE13-16. Yet, the proteomic profile associated with these gross 
phenotypic changes has not been studied. Our study based on application of label-free 
LC-MS/MS analysis in combination to relative quantification using 3 different 
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strategies, provides the first underlying proteomic changes giving rise to the observed 
phenotype. Specifically our analysis clearly demonstrates downregulation of 
molecules related to neuron/axon regeneration and synaptic plasticity, also indicating 
neurodegeneration especially during the chronic phase of the syndrome. In parallel, 
activation of microglial cells and regulation of inflammation is predicted even at the 
3dpi time-point, suggesting astroglial mediated inflammatory response initiating early 
and persisting during the chronic phase of epilepsy.  
Combination of three label-free quantification approaches 
Label-free quantification strategies have been widely utilized in shotgun proteomic 
analyses due to their ease of use in detecting differences in protein abundance in 
biological samples. In this study, we employed a combination of three such 
quantification approaches, SC, top three TIC and top three PI, each one based on a 
different feature of the LC-MS/MS data analysis for protein quantification. In 
particular, these approaches which are based on Spectral count, MS/MS intensity and 
MS1 intensity, respectively, have been shown to have certain advantages and 
limitations (also described in the introduction section). In brief, SC has been 
considered as a more sensitive approach in detecting proteins that undergo changes in 
abundance, in comparison to intensity based approaches23. MS/MS TIC has been 
shown to improve sensitivity in detection of relative changes in low abundant 
proteins, in comparison to SC21. On the other hand, peak area intensity measurements 
are considered to have better performance than MS2-based approaches, regarding 
reproducibility and quantitative dynamic range48. More interestingly, it has been 
suggested that SC-based protein abundance measurements are comparable to 
intensity-based approaches (PI) with respect to correlation with gene expression 
data49. Based on the presented data, we believe that no solid conclusions may be 
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drawn with respect to superiority of one approach versus the others. Similar proteins 
in terms of GO annotations were found to be enriched by all approaches (data not 
shown), and there is general agreement in the expression trends among overlapping 
proteins (Supplementary Table 1). The added value of using all 3 approaches is 
mainly in prioritizing and shortlisting differentially expressed proteins, in such a 
multi-parametric (high number of variables, low n) quantification approach, hence 
increasing reliability of presented conclusions. 
Deregulation of a limited number of immediate response proteins 
Following KA administration, a small number of immediate early response proteins 
were regulated, as depicted by protein expression changes at 1dpi. Proteins interacting 
with or regulating glutamate receptors and involved in neuronal plasticity were found 
to be down-regulated in KA- versus NaCl- injected mice: these include 
Neurochondrin (Ncdn36; down-regulated by 0.66 fold), Homer138 (down-regulated by 
0.53 fold) and Shank 3 (SH3 and multiple ankyrin repeat domains protein 3; detected 
only in NaCl-injected mice at 1dpi and earlier shown to interact with Homer 140). 
According to recent studies, Homer 1 is increased in hippocampus right after status 
epilepticus in another model of TLE50, but downregulated in microarray analysis of 
human TLE samples51, in line to our studies. Similarly, Ataxin-10 was also detected 
only in NaCl-injected mice; this protein is widely expressed in the brain and has been 
involved in induction of neuritogenesis39. Neurabin-2 (Spinophilin), a scaffolding 
protein of neuronal dendritic spines that regulates synaptic transmission37 was 
downregulated at 1dpi in KA-injected mice (0.33 fold). On the other hand, one of the 
upregulated proteins, nucleophosmin (2 fold), regulates key cellular processes, 
directly linked to proliferation42, 52. Recently it was suggested that nucleophosmin, in 
the case of insult, may act as a coordinator of a response that can lead to cell death42. 
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Altogether, these data suggest that impairment of synaptic plasticity is already evident 
during the so-called "silent period" that follows status epilepticus.  
Downregulation of neuronal related proteins is indicative of neurodegeneration 
TLE is characterized pathologically by hippocampal sclerosis, a characteristic 
morphologic change associated with massive hippocampal neuronal loss localized in 
the hilus of the dentate gyrus, as well as in the CA1 and CA3 hippocampal regions53. 
Similar histopathological features are observed in the KA treated mouse model of 
MTLE13-16. Proteomic analysis revealed that during epileptogenesis, i.e. at 3dpi, 
several molecules related to neuron projection, axon and dendrite development as well 
as synaptic plasticity and transmission were downregulated. Most of these proteins 
were also found to be downregulated at 30dpi, suggesting a sustaining phenomenon of 
neurodegeneration (Table 4). More specifically, Brain-specific angiogenesis inhibitor 
1-associated protein 2, an abundant component of the postsynaptic density, shown to 
interact with Rac and ProSAP/Shank proteins and considered a regulator of 
hippocampal synaptic plasticity54, 55 as well as Brain-specific serine/threonine-protein 
kinase 1, a presynaptic regulator of neurotransmitter release56, were significantly 
downregulated (0.37 fold, 3dpi; 0.16 fold, 30dpi) or detected only in NaCl-injected 
animals at 3dpi, respectively. Shank3, which interacts with metabotropic glutamate 
receptors, was again detected only in NaCl-injected animals at 3dpi, as in the case of 
1dpi. Molecules involved in synaptic transmission, such as Neurabin-2, (also involved 
in antigen presentation of dendritic cells)37, and A-kinase anchor protein 5 (Akap5), a 
postsynaptic scaffold molecule involved in long term potentiation57, were consistently 
downregulated [0.33 (1dpi), 0.3 (3dpi), 0.4 (30dpi)] in KA-injected animals or 
detected only in NaCl animals (3dpi, 30dpi), respectively. Another molecule that 
seems to be involved in regulation of neuronal spine density is Src substrate cortactin 
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(Cttn), which was also found to be downregulated in KA-injected mice at 1dpi (0.53 
fold), 3dpi (0.47 fold) and at 30dpi (0.13 fold)58. Neuron specific microtubule-
associated proteins Map1a, Map2, tau (Mapt), Map1b and Map6, participating in the 
development of neuronal polarity59-64 were found to be down-regulated: Map2 
consistently downregulated in all three time-points after KA injection [by 0.53 (1dpi), 
0.53 (3dpi) and 0.43 (30dpi)], Map1a at 3 and 30dpi [0.6 (3dpi), 0.43 (30dpi)] and tau, 
Map1b and Map6 at 30dpi (tau: 0.37, Map1b: 0.43 and Map6: 0.3 fold). Drebrin-like 
protein (Abp1), which plays an important role on synaptic organization and neuron 
morphogenesis65, was significantly downregulated (0.2 fold) at KA-injected mice at 
30dpi. Paralemmin-1, which is required for dendritic spine maturation through 
filopodia induction, was also downregulated in KA-injected animals 30dpi (0.2 
fold)66. 
Interestingly, many molecules related to glutamate signaling and GABA synthesis, 
such as Disks large homolog 4 (PSD-95), Disks large homolog 2 (PSD-93) that 
interact with NMDA receptors and Band 4.1-like protein 3 that interacts with AMPA 
receptors, were downregulated by 0.3, 0.23 and 0.43 fold respectively, in KA-injected 
mice at 30dpi. This later result could be expected since KA is an agonist of the 
kainate receptors14, 67 and is in line with our recent report in the same model showing 
a reduced expression of several subunits of NMDA and AMPA receptor (Stamboulian 
et al, under submission). However, further studies are still needed to clarify the 
involvement of these proteins of the glutamate receptor signaling pathway to the 
development of the epileptic phenotype in the KA model. Moreover, expression of 
Protein kinase C gamma type (PKC gamma), which binds to GLUR4 and NMDAR1 
neuronal receptors and plays a key role in neuronal signal transduction as well as in 
protection from oxidative stress68, 69 was also downregulated in KA-injected mice at 
Page 23 of 50
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24 
 
30dpi (0.59 fold). Taken together these findings further confirm and provide the 
molecular background of the established phenotype of neurodegeneration observed in 
the KA mouse model.  
Consistent upregulation of proteins related to microglia/astrocyte activation and 
inflammatory response 
Inflammation in the brain and the rest of the central nervous system (CNS) is a key 
factor in development of neurodegeneration60. Although the CNS has been considered 
to be immunologically privileged, as peripheral circulating immune cells have only 
limited access to it, dynamic immune and inflammatory processes occur in response 
to different stimuli60. Microglia is a first line of defense in response to CNS injuries or 
immunologic stimuli. It is activated, undergoes phagocytosis, antigen presentation, 
proliferation and releases inflammatory mediators, such as cytokines, chemokines, 
nitric oxide and ROS61. Although the initial neuroinflammation is protective for the 
CNS, in specific pathological conditions, it can persist long after an initial insult. This 
inflammatory response mobilizes other cells like astrocytes, T cells and even neurons, 
which participate in a self-perpetuating neurotoxic phenomenon61. In MTLE many 
alterations in the intermediate and chronic phase after injury, such as abnormal 
migration of neurons, aberrant synaptic reorganization, greatly declined neurogenesis 
and sustained inflammation, have been reported25. In brain tissue from epileptic 
patients, astrocytes undergo significant changes in their physiological properties, and 
are involved in the activation of inflammatory pathways70. In particular, reactive 
astrogliosis with modified astroglial function may play an important role in the 
generation and spread of seizure activity71. It has been suggested that 
proinflammatory molecules can change glio-neuronal communications and contribute 
to the generation of seizures and seizure-related neuronal damage70.  
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In the KA MTLE mouse model, our data obtained at 30dpi show that proteins mainly 
expressed by astrocytes and microglia were upregulated or expressed only in epileptic 
mice, suggesting glial cell activation and/or astrocyte differentiation. Some of these 
proteins were already significantly upregulated at 3dpi (Table 4), suggesting that this 
effect on astrocytes is initiated during epileptogenesis, in line with previous 
findings25. At the same time-point a significant number of molecules related to 
inflammation and immune response was upregulated, also in support of an 
astrocyte/microglial-mediated inflammatory response.  
In particular, GFAP and Vimentin, markers of astrocyte and radial glial cells, 
respectively35, 72-74 were found to be upregulated at 3dpi (GFAP: 1.9 fold; Vimentin: 
2.1 fold), and 30dpi (GFAP: 12.5 fold; Vimentin: 8 fold). Along the same lines, 
Clusterin (Sulfated glycoprotein 2, SGP-2, or apolipoprotein J), predominantly 
expressed in astrocytes and suggested to be neuroprotective in neurodegenerative 
diseases75 ,was upregulated at 3dpi in KA-injected mice (2.5 fold) and even more at 
30 dpi (37.5 fold). Along the same lines, Apolipoprotein E (ApoE), main 
apolipoprotein expressed by astrocytes and potential modulator of inflammation76, 77. 
and Gelsolin, mainly expressed by activated microglia and astrocytes78 and with 
potential protective role against neuroinflammation in the brain79, were also 
upregulated in KA-injected mice (5.2 fold and 6.4 fold respectively) at 30dpi. 
Additional astrocyte or microglial markers found to be upregulated at 30dpi include, 
Aldehyde dehydrogenase 1 family, member L1 (Aldh1L1)80, as well as Allograft 
inflammatory factor 1 (Iba-1)81, collectively all suggesting significant glial activation 
at the chronic phase of MTLE. 
In support of this hypothesis, a significant number of molecules related to 
inflammation and immune response were also found to be upregulated in KA vs 
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NaCl-injected animals, at 30dpi. Specifically, it has been suggested that activation of 
microglia induces the release of proinflammatory cytokines as well as complement 
components82. Along these lines, serum acute phase proteins produced upon tissue 
inflammation, such as complement C4B and the inflammatory marker alpha-2-
macroglobulin83 were detected only in KA-injected mice at 30dpi. In addition, 
Galectin-1, earlier reported to be abundantly present at inflammation and injury sites, 
and also shown to be upregulated in degenerating neurons84, 85 was detected only in 
KA-injected mice. Along the same lines, Cystatin-c, earlier reported to be upregulated 
during chronic epilepsy, implicated with decreased neurogenesis and recently been 
considered as marker of inflammation86, was significantly upregulated in KA-injected 
mice at 30dpi (4.1 fold). Additional molecules related to immune responses and found 
to be expressed only in KA-injected animals at 30dpi included CD4487, two integrin 
receptors, Integrin alpha-V (CD51) and Integrin beta-2 (CD18) expressed by T cells88, 
and Platelet-activating factor acetylhydrolase, a molecule with potent pro-
inflammatory properties89.  
Taken together, these findings suggest that signs of neuroinflammation, likely 
mediated through astrocyte and microglia activation, in the hippocampus of MTLE 
mice are evident at 3dpi, during epileptogenesis, and persist during the chronic phase 
of epilepsy up to 30dpi.  
Validation of findings in other studies of human/mouse MTLE samples 
The KA mouse model used in this study is a well-established model of MTLE. It 
reproduces most of the behavioral, electrophysiological, histological and 
pharmacological features observed in human patients suffering of MTLE, as depicted 
by clinical epileptologists47, 90, 91. A large number of publications have used this model 
including recent investigations on the most commonly used antiepileptic drugs13-16, 47. 
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Nevertheless, similarities of the mouse model to the human condition at the molecular 
level have not been investigated, as to the best of our knowledge there is not enough 
human data yet to allow such quantification of molecular similarities. As a first effort 
in this direction, we crosschecked our proteomic findings in existing studies of human 
MTLE samples. As mentioned previously, at 30dpi mice have regular and stable focal 
seizures with no further evolution, thereby this time-point is considered to correspond 
to the chronic state of the disease, hence be reflective of the observed human 
condition16, 47. As we can see in detail in Table 6, mouse data from 30dpi are in very 
good agreement with genomic or proteomic data from human MTLE samples, 
validating the increased relevance of this model to human MTLE91. Even though such 
analysis to be completed further requires a more detailed cross-species evaluation of 
orthologues, various interesting observations can already be made: Our data are in 
good agreement with DNA microarray data analyzing the gene expression profile of 
sclerotic hippocampi surgically removed from TLE patients51. In particular, GFAP, 
GMP reductase, Moesin and CD44 were upregulated, whereas DLG4, Homer 1, 
Synapsin-1, MAP2K4 and PTK2B (FAK2) were downregulated according to the 
microarray analysis51, in line to our proteomics results. Interestingly, GFAP Moesin 
MAP2K4, PTK2B and Homer1 were detected as being differentially expressed, from 
a very early time-point (3dpi) in the mouse model. Their further investigation as 
potential early markers for the human syndrome is warranted. In other microarray 
studies of human MTLE samples, Serotransferrin and Tenancin were upregulated 
while Amphiphysin was downregulated, in good accordance with our data12, 92, 93. 
When proteomic analysis using two-dimensional gel electrophoresis (2-DE) coupled 
with mass spectrometry was performed in human MTLE hippocampi, differential 
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expression of Ezrin (up, 5.3 fold) and Map2k4 (down, 0.56 fold) was suggested, in 
agreement with our findings94.  
Besides the relevance to the human pathology, additional proteomic changes reported 
in our study were also observed in other studies using the KA mouse model of MTLE, 
mainly by immunohistochemistry. Specifically, elevated expression of the astocyte 
marker GFAP was validated at several time-points, 3dpi, 7dpi, 14dpi and 6 weeks 
post KA injection15, 25 (Table 6). Moreover, upregulation of the microglial marker Iba-
1 has also been verified in KA-injected animals at 7dpi15 and 14dpi 95.  
Uncovering the underlying molecular mechanisms involved in MTLE is critical to 
obtain a better understanding of the pathophysiology of epileptogenesis. Our study, 
relying on the use of robust proteomic approaches in combination to targeted MRM 
analysis, provides a comprehensive molecular background associated with 
deregulation of neuronal processes even at 1dpi, followed by activation of microglia, 
induced inflammation and neurodegeneration during epileptogenesis, sustained and 
significantly expanded at the chronic phase of the epilepsy. Even though further 
studies are needed to confirm the biological relevance of these findings, their 
agreement in several cases with those of available studies using human samples, 
further enhances the applicability of this model in drug development and forms the 
basis for new studies addressing the upstream regulators of the observed astroglial 
inflammatory response.  
 
 
 
 
 
Page 28 of 50
ACS Paragon Plus Environment
Journal of Proteome Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29 
 
FIGURE LEGENDS 
Figure 1 
Time course of GFAP expression in the dentate gyrus after unilateral 
intrahippocampal KA injection. (A) All mice included in the study exhibited an 
increase of GFAP expression as shown by the proteomics analysis. Upregulation by 
1.3 (not reaching statistical significance), 1.9 and 12.5 fold, (average of the three 
quantification approaches), was detected at 1dpi, 3dpi and 30dpi, respectively 
(n=5/group). Data from spectral counts are presented, similar results were obtained 
from all approaches. (B) Confocal images showing double immunostaining for GFAP 
(green) and Hoechst (blue) on ipsilateral sections of the dentate gyrus at 1dpi (i), 3dpi 
(ii) and 30dpi (iii), (n=4/group). (i-iii) GFAP gradual upregulation in the dentate 
gyrus is shown, reaching maximum levels at 30dpi. Hoechst staining shows 
dispersion of the dentate gyrus especially at 30 d post KA injection. (iv) Minimum 
GFAP expression levels were detected on ipsilateral sections of the dentate gyrus of 
control NaCl-injected mice; representative image at 30dpi is shown. Magnification 
20x. (C) Semi-quantitative analysis of GFAP expression based on the 
immunohistochemistry images. Gradual increase of 1.6, 2 and 3.9 fold is observed at 
1dpi, 3dpi and 30dpi, respectively, in comparison to NaCl controls (n=4/group, 
Student’s t-test). The number of GFAP positive cells per 100mm2 is depicted (ImageJ 
software). 
Figure 2 
Overview of the proteomic findings of KA vs NaCl-injected animals, at 1, 3 and 
30dpi. Average number of proteins identified per sample using Scaffold software, 
with a peptide FDR<0.05% and at least 2 identified peptides per protein are shown. 
Collected protein lists of all samples (n=5/group) per time-point were merged and 
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then a frequency threshold was applied, as follows. Only proteins present in at least 3 
out of 5 samples or uniquely expressed in at least 3 out of 5 KA or NaCl treated mice, 
were considered for further analysis. Following comparison of KA vs NaCl-injected 
mice at each time-point and statistical analysis, proteins that were differentially 
expressed (fold change≥1.5 or fold≤0.5) and the differential expression was 
statistically significant (p≤0.05, Student's t-test), according to all 3 quantification 
approaches (SC, top three TIC and top three PI), were shortlisted.  
Figure 3 
Functional annotation of differentially expressed proteins. Functional annotation 
of the differentially expressed proteins at 3dpi (A) and 30dpi (B, C) using Gene 
Ontology (biological process), revealed that a number of proteins were related to 
neuron projection, axon and dendrite development, synaptic plasticity as well as 
microglial and astrocyte activation.  
Figure 4 
Validation of selected findings using MRM LC-MS/MS. Representative box plots 
of the intensity of specific proteotypic peptides used for the 
identification/quantification of GFAP, Vimentin and Apolipoprotein-E in KA and 
NaCl treated animals, are shown. A total of 5 samples per category were analyzed.  
 
TABLES 
Table 1 
1dpi – All differentially expressed proteins 
1dpi: Following comparison of KA vs NaCl-injected mice and statistical analysis 
(Student t-test), proteins that were differentially expressed (fold change≥1.5 or fold 
≤0.5) and the differential expression was statistically significant (p≤0.05, Student's t-
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test), according to all 3 quantification approaches (SC, top three TIC and top three 
PI), are shown. Only proteins present in at least 3 out of 5 samples or uniquely 
expressed in at least 3 out of 5 KA or NaCl treated mice, were included. Average of 
the fold change (KA/NaCl) of each quantification approach is shown. Detailed 
information on mean intensities of all proteins and p values for each quantification 
approach are shown in Supplementary Table 1. 
Table 1: 1dpi – All differentially expressed proteins 
Entry name Protein name Gene 
name 
Fold 
change 
TRFE_MOUSE Serotransferrin Tf 3 
NPM_MOUSE Nucleophosmin Npm1 2 
SPRL1_MOUSE SPARC-like protein 1 Sparcl1 KA only 
HEMO_MOUSE Hemopexin Hpx KA only 
NEB2_MOUSE Neurabin-2 Ppp1r9b 0.33 
AGAP2_MOUSE Arf-GAP with GTPase, ANK repeat and PH 
domain-containing protein 2 
Agap2 0.4 
FAK2_MOUSE Protein-tyrosine kinase 2-beta Ptk2b 0.4 
MTAP2_MOUSE Microtubule-associated protein 2 Map2 0.53 
SRC8_MOUSE Src substrate cortactin Cttn 0.53 
HOME1_MOUSE Homer protein homolog 1 Homer1 0.53 
NCDN_MOUSE Neurochondrin Ncdn 0.66 
PROSC_MOUSE Proline synthase co-transcribed bacterial 
homolog protein 
Prosc NaCl only 
SPB6_MOUSE Serpin B6 Serpinb6 NaCl only 
COR1B_MOUSE Coronin-1B Coro1b NaCl only 
EXOC8_MOUSE Exocyst complex component 8 Exoc8 NaCl only 
OAT_MOUSE Ornithine aminotransferase, mitochondrial Oat NaCl only 
PSME1_MOUSE Proteasome activator complex subunit 1 Psme1 NaCl only 
ATX10_MOUSE Ataxin-10 Atxn10 NaCl only 
WDR47_MOUSE WD repeat-containing protein 47 Wdr47 NaCl only 
ELMO2_MOUSE Engulfment and cell motility protein 2 Elmo2 NaCl only 
EPN2_MOUSE Epsin-2 Epn2 NaCl only 
SHAN3_MOUSE SH3 and multiple ankyrin repeat domains 
protein 3 
Shank3 NaCl only 
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Table 2 
3dpi: Differentially expressed proteins (selected) 
3dpi: Following comparison of KA vs NaCl-injected mice and statistical analysis 
(Student t-test), proteins that were differentially expressed (fold change≥1.5 or fold 
≤0.5) and the differential expression was statistically significant (p≤0.05, Student's t-
test), according to all 3 quantification approaches (SC, top three TIC and top three 
PI), were shortlisted. Functional annotation of these proteins at 3dpi using Gene 
Ontology (biological process), revealed a number of proteins which are related to 
neuron projection, axon and dendrite development, synaptic plasticity as well as 
microglial and astrocyte activation. Only proteins present in at least 3 out of 5 
samples or uniquely expressed in at least 3 out of 5 KA or NaCl treated mice, were 
included. Average of the fold change (KA/NaCl) of each quantification approach is 
shown. Detailed information on mean intensities of all proteins and p values for each 
quantification approach are shown in Supplementary Table 1.  
Table 2: 3dpi: Differentially expressed proteins (selected) 
Entry name Protein name Gene 
name 
Fold 
change 
neuron projection, axon and dendrite development and synaptic plasticity 
FLNA_MOUSE Filamin-A Flna 6.4 
NEB2_MOUSE Neurabin-2 Ppp1r9b 0.3 
MTAP2_MOUSE Microtubule-associated protein 2 Map2 0.53 
MAP1A_MOUSE Microtubule-associated protein 1A Map1a 0.6 
BAIP2_MOUSE Brain-specific angiogenesis inhibitor 1-
associated protein 2 
Baiap2 0.36 
SRC8_MOUSE Src substrate cortactin Cttn 0.47 
SC6A1_MOUSE Sodium- and chloride-dependent GABA 
transporter 1 
Slc6a1 0.53 
AKAP5_MOUSE A-kinase anchor protein 5 Akap5 NaCl only 
BRSK1_MOUSE Brain-specific serine/threonine-protein kinase 
1 
Brsk1 NaCl only 
SHAN3_MOUSE SH3 and multiple ankyrin repeat domains 
protein 3 
Shank3 NaCl only 
gliosis and inflammation   
MOES_MOUSE Moesin Msn 8.3 
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CLUS_MOUSE Clusterin Clu 2.7 
VIME_MOUSE Vimentin Vim 2.1 
GFAP_MOUSE Glial fibrillary acidic protein Gfap 1.9 
FAK2_MOUSE Protein-tyrosine kinase 2-beta Ptk2b 0.36 
 
Table 3 
30dpi: differentially expressed proteins (selected) 
30dpi: Following comparison of KA vs NaCl-injected mice and statistical analysis 
(Student t-test), proteins that were differentially expressed (fold change≥1.5 or fold 
≤0.5) and the differential expression was statistically significant (p≤0.05, Student's t-
test), according to all 3 quantification approaches (SC, top three TIC and top three 
PI), were shortlisted. Functional annotation of these proteins at 30dpi using Gene 
Ontology (biological process), revealed a number of proteins which are related to 
neuron projection, axon and dendrite development, synaptic plasticity as well as 
microglial/astrocyte activation and inflammation. Only proteins present in at least 3 
out of 5 samples or uniquely expressed in at least 3 out of 5 KA or NaCl treated mice, 
were included. Average of the fold change (KA/NaCl) of each quantification 
approach is shown. Detailed information on mean intensities of all proteins and p 
values for each quantification approach are shown in Supplementary Table 1.  
Table 3: 30dpi: differentially expressed proteins (selected) 
neuron projection, axon and dendrite development and synaptic plasticity 
Entry name  Protein name Gene 
name  
Fold 
change 
FLNA_MOUSE Filamin-A Flna KA only 
TENA_MOUSE Tenascin Tnc KA only 
USP9X_MOUSE Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X 
Usp9x KA only 
ITM2C_MOUSE Integral membrane protein 2C Itm2c KA only 
MYO6_MOUSE Unconventional myosin-VI Myo6 KA only 
ANM1_MOUSE Protein arginine N-methyltransferase 1 Prmt1 KA only 
SRC8_MOUSE Src substrate cortactin Cttn 0.13 
BAIP2_MOUSE Brain-specific angiogenesis inhibitor 1-
associated protein 2 
Baiap2 0.16 
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DBNL_MOUSE Drebrin-like protein Dbnl 0.2 
PALM_MOUSE Paralemmin-1 Palm 0.2 
DLG2_MOUSE Disks large homolog 2 Dlg2 0.23 
E41L3_MOUSE Band 4.1-like protein 3 Epb41l3 0.26 
DLG4_MOUSE Disks large homolog 4 Dlg4 0.3 
MAP6_MOUSE Microtubule-associated protein 6 Map6 0.3 
PCP4_MOUSE Purkinje cell protein 4 Pcp4 0.33 
SYGP1_MOUSE Ras/Rap GTPase-activating protein 
SynGAP 
Syngap1 0.33 
TAU_MOUSE Microtubule-associated protein tau Mapt 0.37 
SC6A1_MOUSE Sodium- and chloride-dependent GABA 
transporter 1 
Slc6a1 0.37 
NEB2_MOUSE Neurabin-2 Ppp1r9b 0.4 
AP180_MOUSE Clathrin coat assembly protein AP180 Snap91 0.4 
MAP1B_MOUSE Microtubule-associated protein 1B Map1b 0.43 
MAP1A_MOUSE Microtubule-associated protein 1A Map1a 0.43 
MTAP2_MOUSE Microtubule-associated protein 2 Map2 0.43 
PP2BA_MOUSE Serine/threonine-protein phosphatase 2B 
catalytic subunit alpha isoform 
Ppp3ca 0.5 
SYN1_MOUSE Synapsin-1 Syn1 0.5 
SYN2_MOUSE Synapsin-2 Syn2 0.5 
DPYL3_MOUSE Dihydropyrimidinase-related protein 3 Dpysl3 0.53 
MP2K1_MOUSE Dual specificity mitogen-activated protein 
kinase kinase 1 
Map2k1 0.56 
KPCG_MOUSE Protein kinase C gamma type Prkcg 0.59 
1433F_MOUSE 14-3-3 protein eta Ywhah 0.59 
1433B_MOUSE 14-3-3 protein beta/alpha Ywhab 0.59 
1433T_MOUSE 14-3-3 protein theta Ywhaq 0.59 
1433G_MOUSE 14-3-3 protein gamma Ywhag 0.63 
1433E_MOUSE 14-3-3 protein epsilon Ywhae 0.66 
GRIN1_MOUSE G protein-regulated inducer of neurite 
outgrowth 1 
Gprin1 NaCl only 
LPPR4_MOUSE Lipid phosphate phosphatase-related 
protein type 4 
Lppr4 NaCl only 
NCS1_MOUSE Neuronal calcium sensor 1 Ncs1 NaCl only 
NPTX1_MOUSE Neuronal pentraxin-1 Nptx1 NaCl only 
RPGF2_MOUSE Rap guanine nucleotide exchange factor 2 Rapgef2 NaCl only 
AKAP5_MOUSE A-kinase anchor protein 5 Akap5 NaCl only 
CPLX1_MOUSE Complexin-1 Cplx1 NaCl only 
gliosis and inflammation   
CLUS_MOUSE Clusterin Clu 37.5 
GFAP_MOUSE Glial fibrillary acidic protein Gfap 12.5 
VIME_MOUSE Vimentin Vim 8 
GELS_MOUSE Gelsolin Gsn 6.4 
APOE_MOUSE Apolipoprotein E ApoE 5.2 
AL1L1_MOUSE Aldehyde dehydrogenase 1 family, Aldh1l1 4.1 
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member L1 
CYTC_MOUSE Cystatin-C Cst3 4.1 
A2MP_MOUSE Alpha-2-macroglobulin-P A2m KA only 
AIF1_MOUSE Allograft inflammatory factor 1 Aif1, 
Iba1 
KA only 
C1QT4_MOUSE Complement C1q tumor necrosis factor-
related protein 4 
C1qtnf4 KA only 
CO4B_MOUSE Complement C4-B C4b KA only 
CD44_MOUSE CD44 antigen Cd44 KA only 
CD9_MOUSE CD9 antigen CD9 KA only 
HA17_MOUSE H-2 class I histocompatibility antigen, Q7 
alpha chain 
H2-Q7 KA only 
ITAV_MOUSE Integrin alpha-V Itgav KA only 
ITB2_MOUSE Integrin beta-2 Itgb2 KA only 
PLSL_MOUSE Plastin-2 Lcp1 KA only 
PAFA_MOUSE Platelet-activating factor acetylhydrolase Pla2g7 KA only 
S10A1_MOUSE Protein S100-A1 S100a1 KA only 
S10A6_MOUSE Protein S100-A6 S100a6 KA only 
LEG1_MOUSE Galectin-1 Lgals1 KA only 
NEB2_MOUSE Neurabin-2 Ppp1r9b 0.4 
PP2BB_MOUSE Serine/threonine-protein phosphatase 2B 
catalytic subunit beta isoform 
Ppp3cb 0.47 
 
Table 4 
Consistently differentially expressed proteins (in more than one time-point). 
Proteins that are consistently differentially expressed in more than one timepoint are 
presented in this table. Average of the ratio (KA/NaCl) of the three quantification 
approaches is shown. Detailed information on mean intensities of all proteins and p 
values (p values≤0.05) for each quantification approach are shown in Supplementary 
Table 1.  
Table 4: Consistently differentially expressed proteins  
(in more than one timepoint) 
Gene Protein 1dpi 3dpi 30dpi 
Trf Serotransferrin 3 2.9 3.7 
Map2 Microtubule-associated 
protein 2 
0.53 0.53 0.43 
Cttn Src substrate cortactin 0.47 0.47 0.13 
Ptk2b Protein-tyrosine kinase 2-
beta 
0.4 0.37 Detected-no 
difference 
Ppp1r9b Neurabin-2 0.33 0.3 0.4 
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Prosc Proline synthase co-
transcribed bacterial 
homolog protein 
NaCl only Detected-no 
difference 
KA only 
Psme1 Proteasome activator 
complex subunit 1 
NaCl only - KA only 
Shank3 SH3 and multiple ankyrin 
repeat domains protein 3 
NaCl only NaCl only - 
Gfap Glial fibrillary acidic protein Detected-no 
difference 
1.9 12.5 
Vim Vimentin Detected-no 
difference 
2 8 
Clu Clusterin Detected-no 
difference 
2.7 37.5 
Dhrs1 Dehydrogenase/reductase 
SDR family member 1 
- 2.6 16.2 
Flna Filamin-A - 6.4 KA only 
Hexb Beta-hexosaminidase subunit 
beta 
- 2.2 KA only 
Map1a Microtubule-associated 
protein 1A 
Detected-no 
difference 
0.6 0.43 
Aak1 AP2-associated protein 
kinase 1 
Detected-no 
difference 
0.43 0.3 
Baiap2 Brain-specific angiogenesis 
inhibitor 1-associated protein 
2 
Detected-no 
difference 
0.36 0.16 
Rph3a Rabphilin-3A Detected-no 
difference 
0.53 0.3 
Slc6a1 Sodium- and chloride-
dependent GABA transporter 
1 
Detected-no 
difference 
0.53 0.37 
G3bp2 Ras GTPase-activating 
protein-binding protein 2 
- 0.43 NaCl only 
Apod Apolipoprotein D - KA only KA only 
Tgm1 Protein-glutamine gamma-
glutamyltransferase K 
- KA only KA only 
Capg Macrophage-capping protein - KA only KA only 
Ctsz Cathepsin Z - KA only KA only 
Akap5 A-kinase anchor protein 5 - NaCl only NaCl only 
 
 Table 5 
Validation of selected findings by MRM LC-MS/MS 
Validation of selected findings by MRM LC-MS/MS approach. Upregulation of 
selected differentially expressed proteins at 30dpi from the LC-MS/MS analysis was 
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verified by targeted MRM approach (n=5/group). The ratio of the intensities (sum of 
transitions) of each peptide and the corresponding p values (Student t-test) are shown, 
in parallel to the respective ratios and p values of the LC-MS/MS analysis. Detailed 
information on the mean intensities of the peptides of each sample are shown in 
Supplementary Table 3.  
Table 5: Validation of selected findings by MRM LC-MS/MS 
LC-MS/MS data MRM data 
Protein KA/NaCl t-test Peptides KA/NaCl t-test 
GFAP 12.5 0.01 AAELNQLR 6.1 0.01 
DNFAQDLGTLR 2.3 0.03 
LEAENNLAAYR 9.9 0.01 
Apolipo-
protein E 5.2 0.01 MEEQTQQIR 4.6 0.01 
TANLGAGAAQPLR 2.1 0.12 
Clusterin 37.5 0.01 LFDSDPITVVLPEEVSK 2.6 0.02 
Vimentin 7.9 0.01 EEAESTLQSFR 6.4 0.01 
Cystatin-C 4.1 0.03 GSNDAYHSR 3.5 0.10 
Galectin-1 KA only FNAHGDANTIVCNTK 11.3 0.01 
Gelsolin 6.4 0.01 SEDCFILDHGR 5.5 0.01 
Homer-1 
(control) 0.8 0.15 TQALSHASSAISK 0.8 0.19 
 
Table 6 
Validation of proteomic findings in other studies of human/mouse MTLE 
samples. In order to correlate our mouse model to the human MTLE syndrome, we 
crosschecked our proteomic findings in existing studies of human MTLE samples. 
Several of our proteomic findings have been confirmed by microarray or proteomics 2 
dimensional electrophoresis (2DE) studies using human samples. In addition, 
proteomic changes reported in our study were also observed in other studies using the 
KA mouse model of MTLE, mainly by immunohistochemistry.  
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Table 6: Validation of proteomic findings in other studies of human/mouse MTLE samples 
 Proteomic findings Other studies 
Protein name 1dpi 3dpi 30dpi  
    Lee et al 2007 51 (human 
TLE hippocampi - 
microarrays)   
GFAP detected/ 
no diff 
up (1.9) up (12.5) up 
GMP reductase 1 - - KA only up 
Moesin - 8.3 - up 
DLG4 - - down (0.3) down 
CD44 - - KA only up 
Homer 1 down  
(0.53) 
- - down  
Synapsin-1 detected/ 
no diff 
detected/ 
no diff 
0.5 down 
MAP2K4 - NaCl only - down  
PTK2B (FAK2) down  
(0.4) 
down 
(0.36) 
detected/ no 
diff 
down  
    Arion et al 2006 93 (human 
temporal cortical samples - 
microarrays) 
Serotransferrin up (3) up (2.9) up (3.7) up (1.9) 
    Jamali et al 2006 92 
(human MTLE entorhinal 
cortex - microarrays)   
Tenascin - - KA only up 
    Venugopal et al 2012 12 
(human TLE samples-
microarrays) 
Amphiphysin - - down (0.43) down 
    Yang et al 2006 94 (human 
MTLE hippocampus- 
proteomics 2DE gels) 
Ezrin - - up (5.3) up (3) 
Map2k1 - - down (0.55) down (0.33) 
    Jessberger et al 2003 50 
(mouse KA MTLE model – 
IHC) 
Homer 1 down  
(0.53) 
- - up 
    Heinrich et al 2006 15 
(mouse KA MTLE model – 
IHC) 
GFAP detected/ 
no diff 
up (1.9) up (12.5) 7dpi up, 14dpi up, 21dpi 
up, 6wpi up  
Vimentin - up (2.1) up (8.0) 21dpi up 
Iba-1 - - KA only 7dpi up 
    Pernot et al 201125  
(mouse KA MTLE model – 
IHC) 
GFAP detected/ up (1.9) up (12.5) 3dpi up, 7dpi up, 21dpi up  
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Supporting Information: Sample variance (Supplementary Figure 1), 
Reproducibility of protein identifications in KA and NaCl-injected animals at 1, 3 and 
30dpi (Supplementary figure 2); Overlap of differentially expressed proteins among 
the three quantification approaches (Supplementary figure 3); All proteins and 
differentially expressed proteins quantified per time-point (Supplementary table 1); 
MRM method development (Supplementary table 2); MRM quantification data 
(Supplementary table 3) 
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